



The Scientific Advisory Board of Chlorion Pharma Ratifies CLP-290 as a Candidate for Full Preclinical Development

LAVAL, QC, July 18 -- Chlorion Pharma Inc. announced today that its Scientific Advisory Board has recommended that CLP-290, a KCC2-modulating small molecule, be advanced in full preclinical development immediately.

The decision was based on data presented by Chlorion's management team, which demonstrated the excellent efficacy, safety and metabolic stability of this compound.

"The final data package for CLP-290 is significantly better than we expected," stated Dr. Martin Gagnon, Chlorion's Vice President & Chief Operating Officer. "With such strong efficacy and a broad therapeutic index, we are confident that CLP-290 will be shown in the clinic to underpin a superior therapeutic strategy for the treatment of neuropathic pain".

Dr. Jeffrey Coull, Chlorion's President & CEO added: "Based on preliminary data, we also expect CLP-290 to exhibit substantial utility in the treatment of other pain conditions".

With full preclinical development of CLP-290 underway, Chlorion is now focusing our discovery efforts on the CL-301 chemical series.

About CLP-290

CLP-290 is an allosteric modulator of the KCC2 cation-chloride co-transporter. The compound demonstrates robust analgesic efficacy in multiple pain models, as well as a broad therapeutic index. Clinical development of CLP-290 is expected to commence in the second quarter of 2009.

About the Company

Chlorion Pharma Inc. is a biopharmaceutical company focused on neurotherapeutics that act via the modulation of chloride in the central nervous system. Presently, the company is developing first-in-class therapeutics for the treatment of neuropathic pain and epilepsy.

For more information, please visit our website at www.chlorion.com.

##